Login Register Cart 0
Generic placeholder image

Anti-Infective Agents

Editor-in-Chief

ISSN (Print): 2211-3525
ISSN (Online): 2211-3533

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Post COVID-19: Risk Factors, Prevention, and Management of Black Fungus

Author(s): Aimen Salman, Suneela Dhaneshwar* and Shaik Shafiulla

Volume 21, Issue 1, 2023

Published on: 12 September, 2022

Article ID: e280422204231 Pages: 15

DOI: 10.2174/2211352520666220428140221

Price: $65

Abstract

Background: Mucormycosis is a genuine, however uncommon shrewd fungal contamination that spreads quickly, and subsequently brief analysis and treatment are important to stay away from the high pace of mortality and morbidity rates. Mucormycosis is brought about by the inward breath of its filamentous (hyphal structure) fungus, particularly in immunosuppressed patients. The pandemic of COVID -19 stays on an upsurge pattern. The second rush of this infection has prompted alarm in numerous nations, including India and a few pieces of the world experiencing the third wave. As there could be no appropriate treatment choices or cures accessible for this lethal contamination, steady consideration gears like oxygen chambers, ventilators and substantial utilization of steroids assume an imperative part in the management of COVID-19. Amidst this pandemic, the COVID-19 patients are procuring optional contaminations, for example, mucormycosis otherwise called black fungus infection.

Objective: It is important to lead research on COVID-19 patients to even more likely to forestall and oversee pioneering contaminations to diminish their occurrence and bleakness. So, this paper is to foster preventive treatment plans and use corticosteroids sanely.

Methods: Using search engines like Embase, PubMed, Google Scholar, etc., various research, review articles, and some book chapters, also various articles on websites and guidelines on the ICMR portal were accessed, after which we prepared this review article. In this review, we have included reported cases and case series of mucormycosis among patients with and without COVID-19 spanning the period of 1969 to 2021 and have described the clinical features and outcomes.

Results: In gentle instances of COVID-19 (without hypoxemia) or when utilizing higher dosages of glucocorticoids, glucocorticoids ought to be kept away from ongoing investigations which have archived a disturbing number of COVID-19 patients with mucormycosis contamination. A large portion of these patients had diabetes which was controlled with the use of steroids.

Conclusion: Thus, the current article underlines mucormycosis and its connected conditions, its component in typical and COVID-19 influenced people, affecting variables and difficulties to defeat this disease. Early distinguishing proof and further examination of its growth will altogether diminish the seriousness of the sickness and death rate in COVID-19- influenced patients.

Keywords: Coronavirus, COVID-19, Mucormycosis, Black fungus, steroids, infection, diabetes mellitus.

Graphical Abstract

[1]
Arastehfar, A.; Carvalho, A.; van de Veerdonk, F.L.; Jenks, J.D.; Koehler, P.; Krause, R.; Cornely, O.A.S.; S. Perlin, D.; Lass-Flörl, C.; Hoenigl, M. COVID-19 associated pulmonary aspergillosis (CAPA)-From immunology to treatment. J. Fungi (Basel), 2020, 6(2), 91.
[http://dx.doi.org/10.3390/jof6020091] [PMID: 32599813]
[2]
Kwon-Chung, K.J. Taxonomy of fungi causing mucormycosis and entomophthoramycosis (zygomycosis) and nomenclature of the disease: Molecular mycologic perspectives. Clin. Infect. Dis., 2012, 54(Suppl. 1), S8-S15.
[http://dx.doi.org/10.1093/cid/cir864]
[3]
Ahmadikia, K.; Hashemi, S.J.; Khodavaisy, S.; Getso, M.I.; Alijani, N.; Badali, H.; Mirhendi, H.; Salehi, M.; Tabari, A.; Mohammadi Ardehali, M.; Kord, M.; Roilides, E.; Rezaie, S. The double-edged sword of systemic corticosteroid therapy in viral pneumonia: A case report and comparative review of influenza-associated mucormycosis versus COVID-19 associated mucormycosis. Mycoses, 2021, 64(8), 798-808.
[http://dx.doi.org/10.1111/myc.13256] [PMID: 33590551]
[4]
Mohammadi, R.; Nazeri, M.; Sayedayn, S. M.; Ehteram, H. A successful treatment of rhinocerebral mucormycosis due to Rhizopus oryzae. J. Res. Med. Sci., 2014, 19(1), 72-74.
[5]
Sipsas, N.V.; Gamaletsou, M.N.; Anastasopoulou, A.; Kontoyiannis, D.P. Therapy of mucormycosis. J. Fungi (Basel), 2018, 4(3), 90.
[http://dx.doi.org/10.3390/jof4030090] [PMID: 30065232]
[6]
Bitar, D.; Van Cauteren, D.; Lanternier, F.; Dannaoui, E.; Che, D.; Dromer, F.; Desenclos, J.C.; Lortholary, O. Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006. Emerg. Infect. Dis., 2009, 15(9), 1395-1401.
[http://dx.doi.org/10.3201/eid1509.090334] [PMID: 19788806]
[7]
Berlin, D.A.; Gulick, R.M.; Martinez, F.J. Severe COVID-19. N. Engl. J. Med., 2020, 383(25), 2451-2460.
[http://dx.doi.org/10.1056/NEJMcp2009575] [PMID: 32412710]
[8]
Horby, P.; Lim, W.S.; Emberson, J.; Mafham, M.; Bell, J.; Linsell, L. RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with COVID-19-preliminary report. N. Engl. J. Med., 2020, 17.
[http://dx.doi.org/10.1056/NEJMoa2021436] [PMID: 32678530]
[9]
Tandon, A.; Tandon, S. COVID-19 and mucormycosis: time we answer questions? J. Assoc. Physicians India, 2021, 69(7), 11-12.
[PMID: 34431281]
[10]
Spellberg, B.; Ibrahim, A.S. Recent advances in the treatment of mucormycosis. Curr. Infect. Dis. Rep., 2010, 12(6), 423-429.
[http://dx.doi.org/10.1007/s11908-010-0129-9] [PMID: 21308550]
[11]
Mahalaxmi, I.; Jayaramayya, K.; Venkatesan, D.; Subramaniam, M.D.; Renu, K.; Vijayakumar, P.; Narayanasamy, A.; Gopalakrishnan, A.V.; Kumar, N.S.; Sivaprakash, P.; Sambasiva Rao, K.R.S.; Vellingiri, B. Mucormycosis: An opportunistic pathogen during COVID-19. Environ. Res., 2021, 201, 111643.
[http://dx.doi.org/10.1016/j.envres.2021.111643] [PMID: 34237335]
[12]
Sugar, A.M. Mucormycosis. Clin. Infect. Dis., 1992, 14(Suppl. 1), S126-S129.
[http://dx.doi.org/10.1093/clinids/14.Supplement_1.S126] [PMID: 1562684]
[13]
Waldorf, A.R. Pulmonary defense mechanisms against opportunistic fungal pathogens. Immunol. Ser., 1989, 47, 243-271.
[PMID: 2490078]
[14]
Mehta, S.; Pandey, A. Rhino-orbital mucormycosis associated with COVID-19. Cureus, 2020, 12(9), e10726.
[http://dx.doi.org/10.7759/cureus.10726] [PMID: 33145132]
[15]
Werthman-Ehrenreich, A. Mucormycosis with orbital compartment syndrome in a patient with COVID-19. Am. J. Emerg. Med., 2021, 42, 264.e5-264.e8.
[http://dx.doi.org/10.1016/j.ajem.2020.09.032] [PMID: 32972795]
[16]
Mekonnen, D.; Mengist, H.M.; Derbie, A.; Nibret, E.; Munshea, A.; He, H.; Li, B.; Jin, T. Diagnostic accuracy of serological tests and kinetics of severe acute respiratory syndrome coronavirus 2 antibody: A systematic review and meta-analysis. Rev. Med. Virol., 2021, 31(3), e2181.
[http://dx.doi.org/10.1002/rmv.2181] [PMID: 33152146]
[17]
Monte Junior, E.S.D.; Santos, M.E.L.D.; Ribeiro, I.B.; Luz, G.O.; Baba, E.R.; Hirsch, B.S.; Funari, M.P.; de Moura, E.G.H. Rare and fatal gastrointestinal mucormycosis (Zygomycosis) in a covid-19 patient: A case report. Clin. Endosc., 2020, 53(6), 746-749.
[http://dx.doi.org/10.5946/ce.2020.180] [PMID: 33207116]
[18]
Pakdel, F.; Ahmadikia, K.; Salehi, M.; Tabari, A.; Jafari, R.; Mehrparvar, G.; Rezaie, Y.; Rajaeih, S.; Alijani, N.; Barac, A.; Abdollahi, A.; Khodavaisy, S. Mucormycosis in patients with COVID-19: A cross-sectional descriptive multicentre study from Iran. Mycoses, 2021, 64(10), 1238-1252.
[http://dx.doi.org/10.1111/myc.13334] [PMID: 34096653]
[19]
Alekseyev, K.; Didenko, L.; Chaudhry, B. Rhinocerebral mucormycosis and COVID-19 pneumonia. J. Med. Cases, 2021, 12(3), 85-89.
[http://dx.doi.org/10.14740/jmc3637] [PMID: 33984095]
[20]
Kim, L.; Garg, S.; O’Halloran, A.; Whitaker, M.; Pham, H.; Anderson, E.J.; Armistead, I.; Bennett, N.M.; Billing, L.; Como-Sabetti, K.; Hill, M.; Kim, S.; Monroe, M.L.; Muse, A.; Reingold, A.L.; Schaffner, W.; Sutton, M.; Talbot, H.K.; Torres, S.M.; Yousey-Hindes, K.; Holstein, R.; Cummings, C.; Brammer, L.; Hall, A.J.; Fry, A.M.; Langley, G.E. Risk factors for intensive care unit admission and in-hospital mortality among hospitalized adults identified through the US coronavirus disease 2019 (COVID-19)-Associated hospitalization surveillance network (COVID-NET). Clin. Infect. Dis., 2021, 72(9), e206-e214.
[http://dx.doi.org/10.1093/cid/ciaa1012] [PMID: 32674114]
[21]
Pasero, D.; Sanna, S.; Liperi, C.; Piredda, D.; Branca, G.P.; Casadio, L.; Simeo, R.; Buselli, A.; Rizzo, D.; Bussu, F.; Rubino, S.; Terragni, P. A challenging complication following SARS-CoV-2 infection: a case of pulmonary mucormycosis. Infection, 2021, 49(5), 1055-1060.
[http://dx.doi.org/10.1007/s15010-020-01561-x] [PMID: 33331988]
[22]
Reynolds, C.J.; Pade, C.; Gibbons, J.M.; Butler, D.K.; Otter, A.D.; Menacho, K.; Fontana, M.; Smit, A.; Sackville-West, J.E.; Cutino-Moguel, T.; Maini, M.K.; Chain, B.; Noursadeghi, M.; Brooks, T.; Semper, A.; Manisty, C.; Treibel, T.A.; Moon, J.C.; Valdes, A.M.; McKnight, Á.; Altmann, D.M.; Boyton, R.; Abbass, H.; Abiodun, A.; Alfarih, M.; Alldis, Z.; Altmann, D.M.; Amin, O.E.; Andiapen, M.; Artico, J.; Augusto, J.B.; Baca, G.L.; Bailey, S.N.L.; Bhuva, A.N.; Boulter, A.; Bowles, R.; Boyton, R.J.; Bracken, O.V.; O’Brien, B.; Brooks, T.; Bullock, N.; Butler, D.K.; Captur, G.; Champion, N.; Chan, C.; Chandran, A.; Collier, D.; Couto de Sousa, J.; Couto-Parada, X.; Cutino-Moguel, T.; Davies, R.H.; Douglas, B.; Di Genova, C.; Dieobi-Anene, K.; Diniz, M.O.; Ellis, A.; Feehan, K.; Finlay, M.; Fontana, M.; Forooghi, N.; Gaier, C.; Gibbons, J.M.; Gilroy, D.; Hamblin, M.; Harker, G.; Hewson, J.; Heywood, W.; Hickling, L.M.; Hingorani, A.D.; Howes, L.; Hughes, A.; Hughes, G.; Hughes, R.; Itua, I.; Jardim, V.; Lee, W-Y.J.; Jensen, M.; Jones, J.; Jones, M.; Joy, G.; Kapil, V.; Kurdi, H.; Lambourne, J.; Lin, K-M.; Louth, S.; Maini, M.K.; Mandadapu, V.; Manisty, C.; McKnight, Á.; Menacho, K.; Mfuko, C.; Mills, K.; Mitchelmore, O.; Moon, C.; Moon, J.C.; Munoz-Sandoval, D.; Murray, S.M.; Noursadeghi, M.; Otter, A.; Pade, C.; Palma, S.; Parker, R.; Patel, K.; Pawarova, B.; Petersen, S.E.; Piniera, B.; Pieper, F.P.; Pope, D.; Prossora, M.; Rannigan, L.; Rapala, A.; Reynolds, C.J.; Richards, A.; Robathan, M.; Rosenheim, J.; Sambile, G.; Schmidt, N.M.; Semper, A.; Seraphim, A.; Simion, M.; Smit, A.; Sugimoto, M.; Swadling, L.; Taylor, S.; Temperton, N.; Thomas, S.; Thornton, G.D.; Treibel, T.A.; Tucker, A.; Veerapen, J.; Vijayakumar, M.; Welch, S.; Wodehouse, T.; Wynne, L.; Zahedi, D.; Chain, B. Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. Science, 2021, 372(6549), eabh1282.
[http://dx.doi.org/10.1126/science.abh1282] [PMID: 33931567]
[23]
Saldanha, M.; Reddy, R.; Vincent, M.J. Paranasal mucormycosis in COVID-19 patient. Indian J. Otolaryngol. Head Neck Surg., 2021, 1-4.
[http://dx.doi.org/10.1007/s12070-021-02574-0]
[24]
Revannavar, S.M.; P S, S.; Samaga, L.; v K, V. COVID-19 triggering mucormycosis in a susceptible patient: a new phenomenon in the developing world? BMJ Case Rep., 2021, 14(4), e241663.
[http://dx.doi.org/10.1136/bcr-2021-241663] [PMID: 33906877]
[25]
Poustchi, H.; Darvishian, M.; Mohammadi, Z.; Shayanrad, A.; Delavari, A.; Bahadorimonfared, A.; Eslami, S.; Javanmard, S.H.; Shakiba, E.; Somi, M.H.; Emami, A.; Saki, N.; Hormati, A.; Ansari-Moghaddam, A.; Saeedi, M.; Ghasemi-Kebria, F.; Mohebbi, I.; Mansour-Ghanaei, F.; Karami, M.; Sharifi, H.; Pourfarzi, F.; Veisi, N.; Ghadimi, R.; Eghtesad, S.; Niavarani, A.; Ali Asgari, A.; Sadeghi, A.; Sorouri, M.; Anushiravani, A.; Amani, M.; Kaveh, S.; Feizesani, A.; Tabarsi, P.; Keyvani, H.; Markarian, M.; Shafighian, F.; Sima, A.; Sadjadi, A.; Radmard, A.R.; Mokdad, A.H.; Sharafkhah, M.; Malekzadeh, R. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study. Lancet Infect. Dis., 2021, 21(4), 473-481.
[http://dx.doi.org/10.1016/S1473-3099(20)30858-6] [PMID: 33338441]
[26]
Johnson, A.K.; Ghazarian, Z.; Cendrowski, K.D.; Persichino, J.G. Pulmonary aspergillosis and mucormycosis in a patient with COVID-19. Med. Mycol. Case Rep., 2021, 32, 64-67.
[http://dx.doi.org/10.1016/j.mmcr.2021.03.006] [PMID: 33842203]
[27]
COVIDSurg Collaborative. Head and neck cancer surgery during the COVID-19 pandemic: An international, multicenter, observational cohort study. Cancer, 2021, 127(14), 2476-2488.
[http://dx.doi.org/10.1002/cncr.33320] [PMID: 33345297]
[28]
Waizel-Haiat, S.; Guerrero-Paz, J.A.; Sanchez-Hurtado, L.; Calleja-Alarcon, S.; Romero-Gutierrez, L. A case of fatal rhino-orbital mucormycosis associated with new onset diabetic ketoacidosis and COVID-19. Cureus, 2021, 13(2), e13163.
[http://dx.doi.org/10.7759/cureus.13163] [PMID: 33575155]
[29]
Placik, D.A.; Taylor, W.L.; Wnuk, N.M. Bronchopleural fistula development in the setting of novel therapies for acute respiratory distress syndrome in SARS-CoV-2 pneumonia. Radiol. Case Rep., 2020, 15(11), 2378-2381.
[http://dx.doi.org/10.1016/j.radcr.2020.09.026] [PMID: 32983308]
[30]
Willeit, P.; Bernar, B.; Zurl, C.; Al-Rawi, M.; Berghold, A.; Bernhard, D.; Borena, W.; Doppler, C.; Kerbl, R.; Köhler, A.; Krause, R.; Lamprecht, B.; Pröll, J.; Schmidt, H.; Steinmetz, I.; Stelzl, E.; Stoiber, H.; von Laer, D.; Zuber, J.; Müller, T.; Wagner, M. Sensitivity and specificity of the antigen-based anterior nasal self-testing programme for detecting SARS-CoV-2 infection in schools, Austria, March 2021. Euro Surveil. Bull., 2021, 26(34), 2100797.
[http://dx.doi.org/10.2807/1560-7917.ES.2021.26.34.2100797]
[31]
Ella, R.; Vadrevu, K.M.; Jogdand, H.; Prasad, S.; Reddy, S.; Sarangi, V.; Ganneru, B.; Sapkal, G.; Yadav, P.; Abraham, P.; Panda, S.; Gupta, N.; Reddy, P.; Verma, S.; Kumar Rai, S.; Singh, C.; Redkar, S.V.; Gillurkar, C.S.; Kushwaha, J.S.; Mohapatra, S.; Rao, V.; Guleria, R.; Ella, K.; Bhargava, B. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: A double-blind, randomised, phase 1 trial. Lancet Infect. Dis., 2021, 21(5), 637-646.
[http://dx.doi.org/10.1016/S1473-3099(20)30942-7] [PMID: 33485468]
[32]
Devauchelle, P.; Jeanne, M.; Fréalle, E. Mucormycosis in burn patients. J. Fungi (Basel), 2019, 5(1), 25.
[http://dx.doi.org/10.3390/jof5010025] [PMID: 30901836]
[33]
Rammaert, B.; Lanternier, F.; Poirée, S.; Kania, R.; Lortholary, O. Diabetes and mucormycosis: A complex interplay. Diabetes Metab., 2012, 38(3), 193-204.
[http://dx.doi.org/10.1016/j.diabet.2012.01.002] [PMID: 22386924]
[34]
Daria, S.; Asaduzzaman, M.; Shahriar, M.; Islam, M.R. The massive attack of COVID-19 in India is a big concern for Bangladesh: The key focus should be given on the interconnection between the countries. Int. J. Health Plann. Manage., 2021, 36(5), 1947-1949.
[http://dx.doi.org/10.1002/hpm.3245] [PMID: 34014016]
[35]
Prakash, H.; Chakrabarti, A. Global Epidemiology of mucormycosis. J. Fungi (Basel), 2019, 5(1), 26.
[http://dx.doi.org/10.3390/jof5010026] [PMID: 30901907]
[36]
John, T.M.; Jacob, C.N.; Kontoyiannis, D.P. When uncontrolled diabetes mellitus and severe COVID-19 converge: The perfect storm for mucormycosis. J. Fungi (Basel), 2021, 7(4), 298.
[http://dx.doi.org/10.3390/jof7040298] [PMID: 33920755]
[37]
Available from: https://www.cdc.gov/fungal/diseases/mucormycosis/statistics.html.eight
[38]
Mahalaxmi, I.; Jayaramayya, K.; Venkatesan, D.; Subramaniam, M.D.; Renu, K.; Vijayakumar, P.; Vellingiri, B. Mucormycosis: An opportunistic pathogen during COVID-19. Environmental Research, 2021.
[39]
Available from: https://www.livemint.com/news/india-records-over-40k-cases-ofmucormycosis-11624875874985.html
[40]
Moona, A.A.; Islam, M.R. Mucormycosis or black fungus is a new fright in India during COVID-19 pandemic: Associated risk factors and actionable items. Public Health Pract. (Oxford, England), 2021, 2, 100153.
[http://dx.doi.org/10.1016/j.puhip.2021.100153]
[41]
Moral, S. Person dies of black fungus, suspect BIRDEM physicians., Available from: https://en.prothomalo.com/bangladesh/reports-first-death-in-black-fungus
[42]
Pillsbury, H. C.; Fischer, N. D. Rhinocerebral mucormycosis. Archiv. Otolaryngol., 1977, 103(10), 600-604.
[http://dx.doi.org/10.1001/archotol.1977.00780270068011]
[43]
McNulty, J.S. Rhinocerebral mucormycosis: Predisposing factors. Laryngoscope, 1982, 92(10 Pt 1), 1140-1143.
[PMID: 7132514]
[44]
Abedi, E.; Sismanis, A.; Choi, K.; Pastore, P. Twenty-five years’ experience treating cerebro-rhino-orbital mucormycosis. Laryngoscope, 1984, 94(8), 1060-1062.
[http://dx.doi.org/10.1288/00005537-198408000-00013 ] [PMID: 6748833]
[45]
Marr, K.A.; Carter, R.A.; Crippa, F.; Wald, A.; Corey, L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis., 2002, 34(7), 909-917.
[http://dx.doi.org/10.1086/339202] [PMID: 11880955]
[46]
Dhiwakar, M.; Thakar, A.; Bahadur, S. Improving outcomes in rhinocerebral mucormycosis--early diagnostic pointers and prognostic factors. J. Laryngol. Otol., 2003, 117(11), 861-865.
[http://dx.doi.org/10.1258/002221503322542854] [PMID: 14670145]
[47]
Khor, B.S.; Lee, M.H.; Leu, H.S.; Liu, J.W. Rhinocerebral mucormycosis in Taiwan. J. Microbial. Immunol. Infect., 2003, 36(4), 266-269.
[48]
Talmi, Y.P.; Goldschmied-Reouven, A.; Bakon, M.; Barshack, I.; Wolf, M.; Horowitz, Z.; Berkowicz, M.; Keller, N.; Kronenberg, J. Rhino-orbital and rhino-orbito-cerebral mucormycosis. Otolaryngol. Head Neck Surg., 2002, 127(1), 22-31.
[http://dx.doi.org/10.1067/mhn.2002.126587] [PMID: 12161726]
[49]
O’Brien, T.J.; McKelvie, P. Rhinocerebral mucormycosis presenting as periorbital cellulitis with blindness: Report of 2 cases. Clin. Exp. Neurol., 1994, 31, 68-78.
[PMID: 7586667]
[50]
Sehgal, A.; Raghavendran, M.; Kumar, D.; Srivastava, A.; Dubey, D.; Kumar, A. Rhinocerebral mucormycosis causing basilar artery aneurysm with concomitant fungal colonic perforation in renal allograft recipient: A case report. Transplantation, 2004, 78(6), 949-950.
[http://dx.doi.org/10.1097/01.TP.0000129798.22312.1E ] [PMID: 15385821]
[51]
Tedder, M.; Spratt, J.A.; Anstadt, M.P.; Hegde, S.S.; Tedder, S.D.; Lowe, J.E. Pulmonary mucormycosis: results of medical and surgical therapy. Ann. Thorac. Surg., 1994, 57(4), 1044-1050.
[http://dx.doi.org/10.1016/0003-4975(94)90243-7] [PMID: 8166512]
[52]
Waldorf, A.R.; Halde, C.; Vedros, N.A. Murine model of pulmonary mucormycosis in cortisone-treated mice. Sabouraudia, 1982, 20(3), 217-224.
[http://dx.doi.org/10.1080/00362178285380321] [PMID: 7135144]
[53]
Morrison, V.A.; McGlave, P.B. Mucormycosis in the BMT population. Bone Marrow Transplant., 1993, 11(5), 383-388.
[PMID: 8504272]
[54]
Rothstein, R.D.; Simon, G.L. Subacute pulmonary mucormycosis. J. Med. Veteran Mycol., 1986, 24(5), 391-394.
[http://dx.doi.org/10.1080/02681218680000591]
[55]
Watts, W.J. Bronchopleural fistula followed by massive fatal hemoptysis in a patient with pulmonary mucormycosis. A case report. Arch. Intern. Med., 1983, 143(5), 1029-1030.
[http://dx.doi.org/10.1001/archinte.1983.00350050193037 ] [PMID: 6591864]
[56]
Pagano, L.; Ricci, P.; Nosari, A.; Tonso, A.; Buelli, M.; Montillo, M.; Cudillo, L.; Cenacchi, A.; Savignana, C.; Melillo, L.; Chierichini, A.; Marra, R.; Bucaneve, G.; Leone, G.; Favero, A.D. Fatal haemoptysis in pulmonary filamentous mycosis: An underevaluated cause of death in patients with acute leukaemia in haematological complete remission. A retrospective study and review of the literature. Gimema Infection Program (Gruppo Italiano Malattie Ematologiche dell’Adulto). Br. J. Haematol., 1995, 89(3), 500-505.
[http://dx.doi.org/10.1111/j.1365-2141.1995.tb08355.x ] [PMID: 7734347]
[57]
Gleissner, B.; Schilling, A.; Anagnostopolous, I.; Siehl, I.; Thiel, E. Improved outcome of zygomycosis in patients with hematological diseases? Leuk. Lymphoma, 2004, 45(7), 1351-1360.
[http://dx.doi.org/10.1080/10428190310001653691] [PMID: 15359632]
[58]
Adam, R.D.; Hunter, G.; DiTomasso, J.; Comerci, G. Jr Mucormycosis: emerging prominence of cutaneous infections. Clin. Infect. Dis., 1994, 19(1), 67-76.
[http://dx.doi.org/10.1093/clinids/19.1.67] [PMID: 7948560]
[59]
Alsuwaida, K. Primary cutaneous mucormycosis complicating the use of adhesive tape to secure the endotracheal tube. Canad. J. Anaesth., 2002, 49(8), 880-882.
[http://dx.doi.org/10.1007/BF03017426]
[60]
Boyd, A.S.; Wiser, B.; Sams, H.H.; King, L.E. Gangrenous cutaneous mucormycosis in a child with a solid organ transplant: a case report and review of the literature. Pediatr. Dermatol., 2003, 20(5), 411-415.
[http://dx.doi.org/10.1046/j.1525-1470.2003.20508.x ] [PMID: 14521558]
[61]
Amin, S.B.; Ryan, R.M.; Metlay, L.A.; Watson, W.J. Absidia corymbifera infections in neonates. Clin. Infect. Dis., 1998, 26(4), 990-992.
[http://dx.doi.org/10.1086/513940] [PMID: 9564488]
[62]
Knoop, C.; Antoine, M.; Vachiéry, J.L.; Depré, G.; Alonso-Vega, C.; Struelens, M.; Van Laethem, J.L.; Lingier, P.; Nagy, N.; Jacobs, F.; Kramer, M.R.; Estenne, M. Gastric perforation due to mucormycosis after heart-lung and heart transplantation. Transplantation, 1998, 66(7), 932-935.
[http://dx.doi.org/10.1097/00007890-199810150-00021 ] [PMID: 9798707]
[63]
Oliver, M.R.; Van Voorhis, W.C.; Boeckh, M.; Mattson, D.; Bowden, R.A. Hepatic mucormycosis in a bone marrow transplant recipient who ingested naturopathic medicine. Clin. Infect. Dis., 1996, 22(3), 521-524.
[http://dx.doi.org/10.1093/clinids/22.3.521] [PMID: 8852973]
[64]
Maraví-Poma, E.; Rodríguez-Tudela, J.L.; de Jalón, J.G.; Manrique-Larralde, A.; Torroba, L.; Urtasun, J.; Salvador, B.; Montes, M.; Mellado, E.; Rodríguez-Albarrán, F.; Pueyo-Royo, A. Outbreak of gastric mucormycosis associated with the use of wooden tongue depressors in critically ill patients. Intensive Care Med., 2004, 30(4), 724-728.
[http://dx.doi.org/10.1007/s00134-003-2132-1] [PMID: 14991098]
[65]
Straatsma, B.R.; Zimmerman, L.E.; Gass, J.D. Phycomycosis. A clinicopathologic study of fifty-one cases. Lab. Invest., 1962, 11, 963-985.
[PMID: 13984484]
[66]
Kauffman, C.A. Zygomycosis: reemergence of an old pathogen. Clin. Infect. Dis., 2004, 39(4), 588-590.
[http://dx.doi.org/10.1086/422729] [PMID: 15356828]
[67]
Imhof, A.; Balajee, S.A.; Fredricks, D.N.; Englund, J.A.; Marr, K.A. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin. Infect. Dis., 2004, 39(5), 743-746.
[http://dx.doi.org/10.1086/423274] [PMID: 15356792]
[68]
Diekema, D.J.; Messer, S.A.; Hollis, R.J.; Jones, R.N.; Pfaller, M.A. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J. Clin. Microbiol., 2003, 41(8), 3623-3626.
[http://dx.doi.org/10.1128/JCM.41.8.3623-3626.2003 ] [PMID: 12904365]
[69]
Girmenia, C.; Moleti, M.L.; Micozzi, A.; Iori, A.P.; Barberi, W.; Foà, R.; Martino, P. Breakthrough Candida krusei fungemia during fluconazole prophylaxis followed by breakthrough zygomycosis during caspofungin therapy in a patient with severe aplastic anemia who underwent stem cell transplantation. J. Clin. Microbiol., 2005, 43(10), 5395-5396.
[http://dx.doi.org/10.1128/JCM.43.10.5395-5396.2005] [PMID: 16208029]
[70]
Blin, N.; Morineau, N.; Gaillard, F.; Morin, O.; Milpied, N.; Harousseau, J.L.; Moreau, P. Disseminated mucormycosis associated with invasive pulmonary aspergillosis in a patient treated for post-transplant high-grade non-Hodgkin’s lymphoma. Leuk. Lymphoma, 2004, 45(10), 2161-2163.
[http://dx.doi.org/10.1080/10428190410001700803] [PMID: 15370266]
[71]
Santos, J.; Espigado, P.; Romero, C.; Andreu, J.; Rivero, A.; Pineda, J. A. Isolated renal mucormycosis in two AIDS patients. Europ. J. Clin. Microbial. Infect. Dis., 1994, 13(5), 430-432.
[http://dx.doi.org/10.1007/BF01972004]
[72]
Selarka, L.; Sharma, S.; Saini, D.; Sharma, S.; Batra, A.; Waghmare, V.T.; Dileep, P.; Patel, S.; Shah, M.; Parikh, T.; Darji, P.; Patel, A.; Goswami, G.; Shah, A.; Shah, S.; Lathiya, H.; Shah, M.; Sharma, P.; Chopra, S.; Gupta, A.; Jain, N.; Khan, E.; Sharma, V.K.; Sharma, A.K.; Chan, A.C.Y.; Ong, J.J.Y. Mucormycosis and COVID-19: An epidemic within a pandemic in India. Mycoses, 2021, 64(10), 1253-1260.
[http://dx.doi.org/10.1111/myc.13353] [PMID: 34255907]
[73]
Szarpak, L.; Chirico, F.; Pruc, M.; Szarpak, L.; Dzieciatkowski, T.; Rafique, Z. Mucormycosis-A serious threat in the COVID-19 pandemic? J. Infect., 2021, 83(2), 237-279.
[http://dx.doi.org/10.1016/j.jinf.2021.05.015] [PMID: 34029629]
[74]
Chamilos, G.; Lewis, R.E.; Kontoyiannis, D.P. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin. Infect. Dis., 2008, 47(4), 503-509.
[http://dx.doi.org/10.1086/590004] [PMID: 18611163]
[75]
Lass-Flörl, C. Zygomycosis: conventional laboratory diagnosis. Clin. Microbial. Infect., 2009, 15(Suppl. 5), 60-65.
[http://dx.doi.org/10.1111/j.1469-0691.2009.02999.x]
[76]
Jensen, H.E.; Salonen, J.; Ekfors, T.O. The use of immunohisto-chemistry to improve sensitivity and specificity in the diagnosis of systemic mycoses in patients with haematological malignancies. J. Pathol., 1997, 181(1), 100-105.
[http://dx.doi.org/10.1002/(SICI)1096-9896(199701)181:1<100::AID-PATH100>3.0.CO;2-O] [PMID: 9072010]
[77]
Pandey, A.; Kaur, G. Mucormycosis revisited: Case report with review of literature. J. Dental Special., 2020, 8(1), 39-44.
[http://dx.doi.org/10.18231/j.jds.2020.010]
[78]
Nair, V.; Sharma, R.K.; Khanna, A.; Talwar, D. Pulmonary mucormycosis diagnosed by convex probe endobronchial ultrasound-guided fine needle aspiration of cavity wall. Lung India, 2017, 34(2), 179-181.
[http://dx.doi.org/10.4103/0970-2113.201320] [PMID: 28360470]
[79]
Safder, S.; Carpenter, J.S.; Roberts, T.D.; Bailey, N. The “Black Turbinate” sign: An early MR imaging finding of nasal mucormycosis. AJNR Am. J. Neuroradiol., 2010, 31(4), 771-774.
[http://dx.doi.org/10.3174/ajnr.A1808] [PMID: 19942703]
[80]
Barnagarwala, T.; Sofi, A. Explained: Why there is shortage of black fungus drug in India. Indian Exp., 2021. Available from: https://indianexpress.com/article/explained/shortage-ofblack-fungus-drug-cases-india-7330327
[81]
Dhama, K.; Khan, S.; Tiwari, R.; Sircar, S.; Bhat, S.; Malik, Y.S.; Singh, K.P.; Chaicumpa, W.; Bonilla-Aldana, D.K.; Rodriguez-Morales, A.J. Coronavirus disease 2019-COVID-19. Clin. Microbiol. Rev., 2020, 33(4), e00028-20.
[http://dx.doi.org/10.1128/CMR]
[82]
Ish, P.; Ish, S. Prevention of mucormycosis in COVID-19 - the need of the hour. Indian J. Ophthalmol., 2021, 69(7), 1969.
[http://dx.doi.org/10.4103/ijo.IJO_1200_21] [PMID: 34146076]
[83]
Oliver, S.E.; Gargano, J.W.; Marin, M.; Wallace, M.; Curran, K.G.; Chamberland, M.; McClung, N.; Campos-Outcalt, D.; Morgan, R.L.; Mbaeyi, S.; Romero, J.R.; Talbot, H.K.; Lee, G.M.; Bell, B.P.; Dooling, K. The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Moderna COVID-19 Vaccine - United States, December 2020. MMWR Morb. Mortal. Wkly. Rep., 2021, 69(5152), 1653-1656.
[http://dx.doi.org/10.15585/mmwr.mm695152e1] [PMID: 33382675]
[84]
Walsh, T.J.; Gamaletsou, M.N.; McGinnis, M.R.; Hayden, R.T.; Kontoyiannis, D.P. Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis). Clin. Infect. Dis., 2012, 54(Suppl. 1), S55-S60.
[http://dx.doi.org/10.1093/cid/cir868] [PMID: 22247446]
[85]
Suganya, R.; Malathi, N.; Karthikeyan, V.; Janagaraj, V.D. Mucormycosis: A brief review. J. Pure Appl. Microbiol., 2019, 13(1), 161-165.
[http://dx.doi.org/10.22207/JPAM.13.1.16]
[86]
Gebremariam, T.; Lin, L.; Liu, M.; Kontoyiannis, D.P.; French, S.; Edwards, J.E., Jr; Filler, S.G.; Ibrahim, A.S. Bicarbonate correction of ketoacidosis alters host-pathogen interactions and alleviates mucormycosis. J. Clin. Invest., 2016, 126(6), 2280-2294.
[http://dx.doi.org/10.1172/JCI82744] [PMID: 27159390]
[87]
Cornely, O.A.; Alastruey-Izquierdo, A.; Arenz, D.; Chen, S.C.A.; Dannaoui, E.; Hochhegger, B.; Hoenigl, M.; Jensen, H.E.; Lagrou, K.; Lewis, R.E.; Mellinghoff, S.C.; Mer, M.; Pana, Z.D.; Seidel, D.; Sheppard, D.C.; Wahba, R.; Akova, M.; Alanio, A.; Al-Hatmi, A.M.S.; Arikan-Akdagli, S.; Badali, H.; Ben-Ami, R.; Bonifaz, A.; Bretagne, S.; Castagnola, E.; Chayakulkeeree, M.; Colombo, A.L.; Corzo-León, D.E.; Drgona, L.; Groll, A.H.; Guinea, J.; Heussel, C.P.; Ibrahim, A.S.; Kanj, S.S.; Klimko, N.; Lackner, M.; Lamoth, F.; Lanternier, F.; Lass-Floerl, C.; Lee, D.G.; Lehrnbecher, T.; Lmimouni, B.E.; Mares, M.; Maschmeyer, G.; Meis, J.F.; Meletiadis, J.; Morrissey, C.O.; Nucci, M.; Oladele, R.; Pagano, L.; Pasqualotto, A.; Patel, A.; Racil, Z.; Richardson, M.; Roilides, E.; Ruhnke, M.; Seyedmousavi, S.; Sidharthan, N.; Singh, N.; Sinko, J.; Skiada, A.; Slavin, M.; Soman, R.; Spellberg, B.; Steinbach, W.; Tan, B.H.; Ullmann, A.J.; Vehreschild, J.J.; Vehreschild, M.J.G.T.; Walsh, T.J.; White, P.L.; Wiederhold, N.P.; Zaoutis, T.; Chakrabarti, A. Mucormycosis ECMM MSG Global Guideline Writing Group. Global guideline for the diagnosis and management of mucormycosis: An initiative of the european confederation of medical mycology in cooperation with the mycoses study group education and research consortium. Lancet Infect. Dis., 2019, 19(12), e405-e421.
[http://dx.doi.org/10.1016/S1473-3099(19)30312-3] [PMID: 31699664]
[88]
Tissot, F.; Agrawal, S.; Pagano, L.; Petrikkos, G.; Groll, A.H.; Skiada, A.; Lass-Flörl, C.; Calandra, T.; Viscoli, C.; Herbrecht, R. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica, 2017, 102(3), 433-444.
[http://dx.doi.org/10.3324/haematol.2016.152900] [PMID: 28011902]
[89]
Astellas Pharma, U. S. Prescribing information for isavuconazonium sulfate, 2018.
[90]
Gil-Lamaignere, C.; Winn, R.M.; Simitsopoulou, M.; Maloukou, A.; Walsh, T.J.; Roilides, E. Inteferon gamma and granulocyte-macrophage colony-stimulating factor augment the antifungal activity of human polymorphonuclear leukocytes against Scedosporium spp.: comparison with Aspergillus spp. Med. Mycol., 2005, 43(3), 253-260.
[http://dx.doi.org/10.1080/13693780412331271072] [PMID: 16010852]
[91]
Zuniga, M.G.; Turner, J.H. Treatment outcomes in acute invasive fungal rhinosinusitis. Curr. Opin. Otolaryngol. Head Neck Surg., 2014, 22(3), 242-248.
[http://dx.doi.org/10.1097/MOO.0000000000000048] [PMID: 24756031]
[92]
Gillespie, M.B.; O’Malley, B.W., Jr; Francis, H.W. An approach to fulminant invasive fungal rhinosinusitis in the immunocompromised host. Arch. Otolaryngol. Head Neck Surg., 1998, 124(5), 520-526.
[http://dx.doi.org/10.1001/archotol.124.5.520] [PMID: 9604977]
[93]
Rahman, F.I.; Islam, M.R.; Bhuiyan, M.A. Mucormycosis or black fungus infection is a new scare in South Asian countries during the COVID-19 pandemic: Associated risk factors and preventive measures. J. Med. Virol., 2021, 93(12), 6447-6448.
[http://dx.doi.org/10.1002/jmv.27207] [PMID: 34260073]
[94]
Kumar, S.; Anche, S.T.; Syed, M.; Dutta, J.; Khan, F.A.; Mali, A.P. Mucormycosis: A New Threat in Pandemic. J. Adv. Med. Dental Sci. Res., 2021, 9(6), 131-135.
[95]
Skiada, A.; Lanternier, F.; Groll, A.H.; Pagano, L.; Zimmerli, S.; Herbrecht, R.; Lortholary, O.; Petrikkos, G.L. European Conference on Infections in Leukemia. Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematologica, 2013, 98(4), 492-504.
[http://dx.doi.org/10.3324/haematol.2012.065110]
[96]
Petrikkos, G.; Skiada, A.; Sambatakou, H.; Toskas, A.; Vaiopoulos, G.; Giannopoulou, M.; Katsilambros, N. Mucormycosis: Ten-year experience at a tertiary-care center in Greece. Europ. J. Clin. Microbial. Infect. Dis., 2003, 22(12), 753-756.
[http://dx.doi.org/10.1007/s10096-003-1035-y]
[97]
Sciubba, J.J.; Regezi, J.A.; Rogers, R.S. PDQ oral disease: Diagnosis and treatment; PMPH-USA, 2002.

Rights & Permissions Print Cite
Article Metrics
3
© 2024 Bentham Science Publishers | Privacy Policy